- Home
- ENIC vs APLS Comparison
ENIC vs APLS Comparison
Compare ENIC & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENIC | APLS |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.2B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ENIC | APLS |
|---|---|---|
| Price | $4.28 | $41.05 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 21 |
| Target Price | N/A | ★ $33.59 |
| AVG Volume (30 Days) | 515.2K | ★ 8.3M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $96,491.22 | N/A |
| Revenue Next Year | $2.63 | $18.19 |
| P/E Ratio | ★ $101.18 | $273.60 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $3.10 | $16.61 |
| 52 Week High | $4.74 | $41.14 |
Technical Indicators
Market Signals| Indicator | ENIC | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 84.57 |
| Support Level | $4.17 | $19.29 |
| Resistance Level | $4.40 | $41.14 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.03 | -0.65 |
| Stochastic Oscillator | 24.99 | 58.33 |
Price Performance
Historical ComparisonAbout ENIC Enel Chile S.A. (Each representing 50 shares of)
Enel Chile SA is an electricity utility company engaged, through its subsidiaries and affiliates, in the generation, transmission, and distribution of electricity across Chile. The Company operates through two main segments: the Generation Business, which includes companies that own and operate power plants supplying electricity to the grid and generates the majority of revenue; and the Distribution and Network Business, which consists of companies operating under public utility concessions to distribute electricity to end customers.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).